Loading..

Agenus Inc. (AGEN) Report Analysis

Corporate Events

Neutral

Agenus Inc. Proposes an Amendment to the Compan...

2022-06-22 21:27:00

Agenus Inc. at its Special Meeting of the stockholders to be held on August 4, 2022, proposed To approve an amendment to the Company’s Amended...

Neutral

Agenus Inc. - Special Call

2022-06-21 09:08:00

To discuss botensilimab/balstilimab combination data in microsatellite stable colorectal cancer (MSS-CRC) presented earlier that day in a late...

Positive

Agenus Inc. Announces Positive Headline Results...

2022-06-10 12:00:00

Agenus Inc. shared that partner GSK announced positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase...

Positive

Agenus Inc. Advances Portfolio with 6 Clinical ...

2022-05-31 12:30:00

Agenus Inc. announced that it has entered into 3 new clinical collaborations with Targovax, Oxford BioTherapeutics, and Immunogenesis, doublin...

Neutral

Agenus Inc. Presents at 2022 Jefferies Global H...

2022-05-25 12:31:00

Agenus Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 11:30 AM. Venue: Marriott Marquis, New York City, New York, U...

Neutral

Oxford BioTherapeutics Announces Collaboration ...

2022-05-25 08:00:00

Oxford BioTherapeutics (OBT) announced that it has entered into a collaboration and supply agreement with Agenus Inc., to support a clinical t...

Neutral

European Society for Medical Oncology., ESMO Wo...

2022-05-24 12:30:00

European Society for Medical Oncology., ESMO World Congress, Jun 29, 2022. Venue: Barcelona, Spain.

Neutral

Agenus Inc. Presents at ESMO World Congress, Ju...

2022-05-24 12:30:00

Agenus Inc. Presents at ESMO World Congress, Jun-29-2022 01:05 PM. Venue: Barcelona, Spain.

Positive

Targovax Announces Clinical Collaboration with ...

2022-05-11 13:35:00

Targovax ASA announced that it has entered into a clinical collaboration and supply agreement with Agenus Inc. to combine Targovax's oncolytic...

Neutral

Agenus Inc. - Shareholder/Analyst Call

2022-04-29 21:25:00

AGM

Neutral

Agenus Inc., Annual General Meeting, Jun 08, 2022

2022-04-29 21:25:00

Agenus Inc., Annual General Meeting, Jun 08, 2022, at 15:30 US Eastern Standard Time. Agenda: To elect Brian Corvese and Timothy R. Wright as ...

Neutral

Agenus Inc. to Report Q1, 2022 Results on May 10, 2022

2022-04-26 12:30:00

Agenus Inc. announced that they will report Q1, 2022 results Pre-Market on May 10, 2022

Neutral

Agenus Inc., Q1 2022 Earnings Call, May 10, 2022

2022-04-26 12:30:00

Agenus Inc., Q1 2022 Earnings Call, May 10, 2022

Positive

Agenus Inc. Presents Data on AGEN1571 (anti-ILT...

2022-04-08 17:00:00

Agenus Inc. announced the first presentation of preclinical data from AGEN1571 – a novel anti-ILT2 antibody designed to modulate tumor-associa...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Positive

Agenus Inc. Announces Publication of Results in...

2021-12-22 13:30:00

Agenus announced the publication of results in the Journal of Clinical Oncology(JCO) from a global Phase 2 clinical study of balstilimab (Bal)...

Neutral

Agenus Inc. Presents at 4th Annual Evercore ISI...

2021-11-17 13:30:00

Agenus Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 01:50 PM. Speakers: Garo H. Armen, Founder, Executi...

Positive

Agenus Announces the Presentation of New Clinic...

2021-11-12 12:00:00

Agenus announced the presentation of new clinical data for AGEN1181 (Fc-enhanced anti-CTLA-4) as monotherapy and in combination with balstilim...

Neutral

Agenus Inc. has filed a Shelf Registration in t...

2021-11-12 00:00:00

Agenus Inc. has filed a Shelf Registration in the amount of $2.8145 million. Security Name: Common Stock Securities Offered: 650,000

Neutral

Agenus Inc. Presents at Society for Immunothera...

2021-11-04 12:30:00

Agenus Inc. Presents at Society for Immunotherapy of Cancer's 36th Annual Meeting, Nov-12-2021 . Venue: Walter E. Washington Convention Center...

Neutral

Agenus Inc., Q3 2021 Earnings Call, Nov 09, 2021

2021-10-25 12:30:00

Agenus Inc., Q3 2021 Earnings Call, Nov 09, 2021

Neutral

Agenus Inc. to Report Q3, 2021 Results on Nov 09, 2021

2021-10-25 12:30:00

Agenus Inc. announced that they will report Q3, 2021 results Pre-Market on Nov 09, 2021

Neutral

Agenus Inc. - Special Call

2021-10-22 12:02:00

To announce a strategic decision to withdraw its Biologics License Application (BLA) for balstilimab, its PD-1 inhibitor

Positive

Agenus Provides Update on Balstilimab Development

2021-10-22 12:02:00

Agenus Inc. announced a strategic decision to withdraw its Biologics License Application (BLA) for balstilimab, its PD-1 inhibitor. The decisi...

Neutral

Agenus Inc. Presents at TIGIT Therapies Digital...

2021-10-12 17:24:00

Agenus Inc. Presents at TIGIT Therapies Digital Summit, Dec-07-2021 . Speakers: Dhan Chand, Scientific Director & Head of Drug Discovery.

Neutral

Agenus Inc. to Receive $20 million Milestone Pa...

2021-10-12 12:30:00

Agenus Inc. announced it has triggered the first development milestone payment under its global licensing agreement with Bristol Myers Squibb ...

Neutral

Hanson Wade Limited, TIGIT Therapies Digital Su...

2021-10-12 06:21:00

Hanson Wade Limited, TIGIT Therapies Digital Summit, Dec 07, 2021 through Dec 09, 2021.

Neutral

Agenus Inc. Presents at BioFuture, Oct-05-2021 01:30 PM

2021-10-05 14:34:00

Agenus Inc. Presents at BioFuture, Oct-05-2021 01:30 PM. Venue: The Lotte Palace Hotel, New York City, New York, United States. Speakers: Jenn...

Neutral

Agenus Inc. Presents at Longwood Healthcare Lea...

2021-09-28 18:44:00

Agenus Inc. Presents at Longwood Healthcare Leaders Conference, Oct-04-2021 04:10 PM. Speakers: Jennifer Buell, President & COO.

Neutral

Longwood Fund, Longwood Healthcare Leaders Conf...

2021-09-28 13:09:00

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021.

Neutral

Agenus Inc. Presents at Festival of Biologics B...

2021-09-22 15:38:00

Agenus Inc. Presents at Festival of Biologics Basel 2021, Nov-09-2021 . Venue: Congress Centre, Basel, Switzerland. Speakers: Emmanuel Briend,...

Neutral

Agenus Inc. Presents at European Society for Me...

2021-09-16 22:25:00

Agenus Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-19-2021 05:35 PM. Venue: Paris Expo Porte de Versaill...

Positive

Agenus Inc. Announces New Subsidiary, SaponiQx

2021-09-10 11:30:00

Agenus Inc. announced the launch of SaponiQx, a subsidiary of Agenus, dedicated to driving innovation in novel adjuvant discovery and vaccine ...

Neutral

Agenus Inc. Presents at H.C. Wainwright 23rd An...

2021-09-09 12:00:00

Agenus Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, Ne...

Neutral

Agenus Inc. Presents at Baird Global Healthcare...

2021-08-26 17:20:00

Agenus Inc. Presents at Baird Global Healthcare Conference 2021, Sep-15-2021 04:20 PM. Speakers: Jennifer Buell, President & COO.

Positive

Agenus Inc. Announces Balstilimab Monotherapy D...

2021-08-26 13:00:00

Agenus Inc. announced that results from a global Phase 2 clinical study of balstilimab monotherapy in recurrent/metastatic cervical cancer wer...

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCO...

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Neutral

Society for Immunotherapy of Cancer, Inc., Soci...

2021-08-17 11:12:00

Society for Immunotherapy of Cancer, Inc., Society for Immunotherapy of Cancer's 36th Annual Meeting, Nov 10, 2021 through Nov 14, 2021. Venue...

Neutral

Robert W. Baird & Co. Incorporated, Baird Globa...

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Negative

Agenus Inc. Promotes Julie DeSander to Chief Bu...

2021-08-09 11:45:00

Agenus Inc. announced that Julie DeSander promoted to Chief Business Officer.

Neutral

Agenus Inc. Presents at BTIG Virtual Biotechnol...

2021-08-02 20:05:00

Agenus Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-09-2021 03:00 PM. Speakers: Jennifer Buell, President & COO.

Negative

Agenus Inc. Announces Resignation of Adam F. Kr...

2021-07-26 20:44:00

On July 20, 2021, Adam F. Krauss, Chief Legal Officer and Chief Compliance Officer of Agenus Inc. provided notice that he will be stepping dow...

Neutral

Agenus Inc. to Report Q2, 2021 Results on Aug 09, 2021

2021-07-26 20:05:00

Agenus Inc. announced that they will report Q2, 2021 results Pre-Market on Aug 09, 2021

Neutral

Agenus Inc., Q2 2021 Earnings Call, Aug 09, 2021

2021-07-26 20:05:00

Agenus Inc., Q2 2021 Earnings Call, Aug 09, 2021

Positive

Agenus Inc. (NasdaqCM:AGEN) acquired Biomanufac...

2021-07-09 00:00:00

Agenus Inc. (NasdaqCM:AGEN) acquired Biomanufacturing Center in Vacaville California, US State from A.G. Spanos Companies on July 9, 2021. Ag...

Neutral

Agenus Inc. Presents at William Blair Biotech F...

2021-07-07 20:05:00

Agenus Inc. Presents at William Blair Biotech Focus Conference 2021, Jul-14-2021 04:20 PM. Speakers: Steven J. O’Day, Chief Medical Officer.

Neutral

Agenus Inc. Announces the Closing of its Global...

2021-07-06 12:30:00

Agenus Inc. announced the closing of its global exclusive license with Bristol Myers Squibb for Agenus’ proprietary bispecific antibody progra...

Positive

Agenus Inc. Announces the U.S. Food and Drug Ad...

2021-07-06 12:30:00

Agenus Inc. announced the U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for this therapy....

Neutral

BTIG, LLC, BTIG Virtual Biotechnology Conferenc...

2021-07-01 10:09:00

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.

Neutral

Agenus Inc. Proposes an Amendment to the Company’s Amended and Restated Articles of Incorporation

2022-06-22 21:27:00

Agenus Inc. at its Special Meeting of the stockholders to be held on August 4, 2022, proposed To approve an amendment to the Company’s Amended and Restated Articles of Incorporation, as amended, to increase the Company’s authorized shares of common stock from 400,000,000 to 800,000,000.

Neutral

Agenus Inc. - Special Call

2022-06-21 09:08:00

To discuss botensilimab/balstilimab combination data in microsatellite stable colorectal cancer (MSS-CRC) presented earlier that day in a late-breaking oral presentation at the ESMO World Congress on Gastrointestinal Cancer in Barcelona, Spain

Positive

Agenus Inc. Announces Positive Headline Results from A Pre-Specified Efficacy Interim Analysis of the Aresvi 006 Phase III Trial Evaluating Their Investigational RSV Vaccine in Adults Aged 60 Years and Above

2022-06-10 12:00:00

Agenus Inc. shared that partner GSK announced positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial evaluating their investigational RSV vaccine in adults aged 60 years and above. The primary endpoint was exceeded with no unexpected safety concerns observed. Engagement with regulators is planned to start immediately with anticipated regulatory submissions in H2 2022. GSK’s RSV vaccine candidate contains Agenus’ proprietary QS-21 STIMULON within its AS01 adjuvant, which – in the context of other antigens – has already demonstrated positive immune responses as well as a favorable safety profile. QS-21 STIMULON is a critical component of the AS01 adjuvant used in multiple GSK vaccines, including GSK’s FDA approved Shingrix shingles vaccine, and the world’s first malaria vaccine Mosquirix, endorsed by the WHO. Agenus’ subsidiary, SaponiQx, has developed a plant cell culture method of manufacturing QS-21 STIMULON, which is designed to support its broader use based on sustainable, scalable, and cost-effective supply. SaponiQx expects to generate GMP material using this process before the end of the year to enable partner clinical trials. Once SaponiQx’s plant cell culture process is fully scaled, Agenus’ wholly-owned manufacturing campus is designed to support the capacity for broad use across disease settings, as well as scalability to address future pandemic threats.

Positive

Agenus Inc. Advances Portfolio with 6 Clinical Collaborations

2022-05-31 12:30:00

Agenus Inc. announced that it has entered into 3 new clinical collaborations with Targovax, Oxford BioTherapeutics, and Immunogenesis, doubling its current number of clinical collaborations. These 6 collaborations span a range of Agenus' clinical assets, including botensilimab, balstilimab, zalifrelimab, and QS-21STIMULON. Agenus is pursuing partnerships with companies developing agents with complementary mechanisms, paving the way for promising immunotherapy combinations to address immunosuppression in the tumor microenvironment. The combination studies are being sponsored and executed by collaborators, with drug supply and scientific support provided by Agenus. This strategy, enabled by in-house integrated manufacturing and scientific capabilities, positions Agenus to achieve the insights and advances needed to drive development on accelerated timelines Tgovax x to conduct a clinical trial combining botensilimab and balstilimab with ONCOS-102 in patients with PD-1 relapsed/refractory melanoma. ONCOS-102 is designed to induce immune activation and immunogenic cell death to improve response to immunotherapy. Oxford BioTherapeutics to conduct a clinical trial combining balstilimab with OBT076 in patients with solid tumors, including lung, gastric, and ovarian cancer. OBT076 is expected to deplete CD205+ cancer cells, and immuno-suppressive cells within the tumor microenvironment, leading to T cell activation and increased response to immunotherapy Immunogenesis to conduct a clinical trial combining balstilimab and zalifrelimab with evofosfamide in patients with advanced solid tumors, including prostate, pancreatic, HPV-negative head and neck cancer. Evofosfamide is anticipated to reduce tumor hypoxia and restore T cell infiltration and activity within the tumor microenvironment, increasing responsiveness to checkpoint therapy. Targovax to conduct a clinical trial combining QS-21 STIMULON with TG01 in up to 3 cancer indications, including multiple myeloma. TG01 is designed to induce T cells that recognize and destroy mut-RAS cancer cells; QS-21 STIMULON is expected to improve immune cell recognition, activation, and TCR diversity of the immune response. Rottapharm Biotech is conducting a clinical trial combining balstilimab with CR6086 in patients with pMMR-MSS colorectal cancer. CR6086 is expected to inhibit the immune suppressive role of prostaglandins in the tumor microenvironment, improving immunogenicity and responsiveness to immunotherapy. The Phase 1/2 study commenced in 2021. Nelum is conducting a clinical trial combining zalifrelimab with NLM-001 and chemotherapy in patients with advanced pancreatic cancer. NLM-001 in combination with chemotherapy is anticipated to condition the tumor microenvironment to improve T cell infiltration, activation, and responsiveness to immunotherapy. The Phase 1/2 study commenced in 2021.

Neutral

Agenus Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 11:30 AM

2022-05-25 12:31:00

Agenus Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 11:30 AM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: Garo H. Armen, Founder, Executive Chairman & CEO, Steven J. O’Day, Chief Medical Officer.

Neutral

Oxford BioTherapeutics Announces Collaboration with Agenus Inc. to Support the Clinical Development of OBT's Antibody Drug Conjugate OBT076 in combination with Agenus' CPI Balstilimab

2022-05-25 08:00:00

Oxford BioTherapeutics (OBT) announced that it has entered into a collaboration and supply agreement with Agenus Inc., to support a clinical trial evaluating the combination of OBT076 with the anti-PD1 checkpoint inhibitor (CPI) balstilimab. OBT has observed near complete responses in two chemotherapy-refractory advanced cancer patients with low to no PD-L1 expression after 2-5 cycles of OBT076 and 1-2 cycles of a CPI, indicating preliminary signs of clinical activity. Immuno-blood profiling during translational work on these patients revealed a potential novel immuno-oncology mechanism for immune system reactivation and tumor shrinkage. OBT plans to evaluate the clinical efficacy of OBT076 in combination with Agenus´ proprietary CPI, balstilimab. Balstilimab is an PD-1 blocking antibody currently in clinical development in several solid tumor indications. Under the terms of the agreement, OBT will be the sponsor of the combination trial and responsible for operational execution, and Agenus will provide drug supply and scientific support. The study will be conducted in the US as well as in several European countries including France, Germany, Belgium and Greece, and will focus on patients with solid tumors including lung, gastric and ovarian cancer.

Neutral

European Society for Medical Oncology., ESMO World Congress, Jun 29, 2022

2022-05-24 12:30:00

European Society for Medical Oncology., ESMO World Congress, Jun 29, 2022. Venue: Barcelona, Spain.

Neutral

Agenus Inc. Presents at ESMO World Congress, Jun-29-2022 01:05 PM

2022-05-24 12:30:00

Agenus Inc. Presents at ESMO World Congress, Jun-29-2022 01:05 PM. Venue: Barcelona, Spain.

Positive

Targovax Announces Clinical Collaboration with Agenus for Upcoming ONCOS-102 Phase 2 Melanoma Trial

2022-05-11 13:35:00

Targovax ASA announced that it has entered into a clinical collaboration and supply agreement with Agenus Inc. to combine Targovax's oncolytic immunotherapy ONCOS-102 with two of Agenus' checkpoint inhibitors in a multi-cohort phase 2 trial to treat anti-PD1 refractory malignant melanoma. Targovax has previously reported a highly competitive 35% objective response rate (ORR) for ONCOS-102 in a phase 1 trial in anti-PD1 refractory melanoma. Importantly, deep translational analyses revealed broad and powerful ONCOS-102-induced immune activation, which correlated with tumor responses and demonstrated strong scientific evidence for additional combination treatments beyond anti-PD1 blockade. Based on these encouraging clinical findings, Targovax is preparing for a multi -cohort phase 2 trial to test ONCOS-102 with novel immunotherapy combinations in a larger number of patients. Agenus is an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and infections. Agenus and Targovax plan to test ONCOS-102 in combination with Agenus' two proprietary checkpoint inhibitors, balstilimab and botensilimab. Balstilimab is an anti-PD1 blocking antibody currently in clinical development in several solid tumors. Botensilimab is an Fc-enhanced anti-CTLA4 antibody that has shown promising activity in early trials in several treatment-resistant solid tumors as monotherapy and in combination with balstilimab.

Neutral

Agenus Inc. - Shareholder/Analyst Call

2022-04-29 21:25:00

AGM

Neutral

Agenus Inc., Annual General Meeting, Jun 08, 2022

2022-04-29 21:25:00

Agenus Inc., Annual General Meeting, Jun 08, 2022, at 15:30 US Eastern Standard Time. Agenda: To elect Brian Corvese and Timothy R. Wright as Class I directors, each for a term of three years expiring at the 2025 Annual Meeting of Stockholders; to approve an amendment to our Amended and Restated Directors' Deferred Compensation Plan (as amended) to increase the number of shares of common stock authorized for issuance; to approve an amendment to 2019 Equity Incentive Plan (as amended) to increase the number of shares of common stock authorized for issuance under such plan; to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022; and to consider any other business as may properly come before the 2022.

Neutral

Agenus Inc. to Report Q1, 2022 Results on May 10, 2022

2022-04-26 12:30:00

Agenus Inc. announced that they will report Q1, 2022 results Pre-Market on May 10, 2022

Neutral

Agenus Inc., Q1 2022 Earnings Call, May 10, 2022

2022-04-26 12:30:00

Agenus Inc., Q1 2022 Earnings Call, May 10, 2022

Positive

Agenus Inc. Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance

2022-04-08 17:00:00

Agenus Inc. announced the first presentation of preclinical data from AGEN1571 – a novel anti-ILT2 antibody designed to modulate tumor-associated macrophages, T, NK and NKT cells. These data are being presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 8, 2022 to April 12, 2022 in New Orleans, LA. Presentation highlights: ILT2 offers a great potential to overcome resistance to approved immunotherapies compared to ILT4. It provides a more prominent and broad expression profile across immune cell types in the tumor microenvironment. AGEN1571 demonstrates superior functional activity compared to the clinical-stage competitor with: approximately 10-fold higher binding affinity to all isoforms of ILT2, enabling superior binding to cells expressing low levels of ILT2. Complete blockade of ILT2-ligand interactions for more effective immune activation and anti-tumor therapeutic potential. Enhanced activation of T, NK, and NKT cells for improved tumor-killing. Superior ability to switch myeloid cells to a pro-inflammatory state, which further boosts T and NK cell immunity. Higher potency in boosting endogenous anti-tumor immunity to synergize with the patient’s anti-tumor antibodies or targeted therapies. Combinations with botensilimab (Fc-enhanced CTLA-4) and other immuno-oncology agents lead to stronger immune cell activation. IND application cleared by the FDA; clinical trial to commence.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Positive

Agenus Inc. Announces Publication of Results in the Journal of Clinical Oncology from a Global Phase 2 Clinical Study of Balstilimab (Bal) Plus Zalifrelimab

2021-12-22 13:30:00

Agenus announced the publication of results in the Journal of Clinical Oncology(JCO) from a global Phase 2 clinical study of balstilimab (Bal) plus zalifrelimab (Zal) in second-line (2L) recurrent/metastatic cervical cancer patients who had relapsed after treatment with platinum-based therapy. The trial showed that in the 125 evaluable patients treated with Bal/Zal, ORR was 25.6%; among PD-L1+ patients, the ORR was 32.8%. The Phase 2 trial was conducted in patients with recurrent/metastatic cervical cancer who had relapsed after prior platinum-based therapy, a population disproportionately represented by younger women, who have limited effective treatment options. Complete and partial responses were achieved by 8.0% and 17.6% of all patients respectively. The disease control rate in the trial was 52.0%. Responses achieved in patients were highly durable, with a median duration of response not yet reached (NR) following 21-month median follow-up (95% CI: 9.7 months to NR). Median overall survival was 12.8 months, with 69.2% and 53.3% of patients remaining alive at 6 and 12 months, respectively. Responses were observed across tumor histologies in the trial. The Bal/Zal combination continued to show no unexpected toxicities and no new safety signals were identified. TRAEs leading to discontinuations occurred in 7.7% of patients.

Neutral

Agenus Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 01:50 PM

2021-11-17 13:30:00

Agenus Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 01:50 PM. Speakers: Garo H. Armen, Founder, Executive Chairman & CEO, Steven J. O’Day, Chief Medical Officer.

Positive

Agenus Announces the Presentation of New Clinical Data for AGEN1181

2021-11-12 12:00:00

Agenus announced the presentation of new clinical data for AGEN1181 (Fc-enhanced anti-CTLA-4) as monotherapy and in combination with balstilimab (anti-PD-1) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting. As of the data cut-off date of September 17, 2021, one hundred and sixteen patients received AGEN1181 in a dose escalation study to determine the optimal monotherapy dose and combination dose with balstilimab. Of note, this population was heavily pre-treated, with over half of these patients receiving at least 3 prior lines of therapy and nearly a third of patients receiving prior anti-PD-1 therapy. There were four cases of confirmed objective responses to AGEN1181 monotherapy. These include a complete response (CR) in MSS endometrial cancer, and partial responses (PR) in pancreatic cancer, as well as PD-1 refractory cervical cancer. These are the first reported responses to CTLA-4 monotherapy in these disease settings. The fourth response was in a patient with PD-1 refractory melanoma. Of note, three of the monotherapy responders expressed the low affinity Fc?RIIIA receptor, which is associated with lack of response to first-generation CTLA-4 inhibitors. Significant benefit was also observed with the combination of AGEN1181 and balstilimab across multiple “cold” cancers studied, with >60% of evaluable patients receiving at least 1 mg/kg AGEN1181 experiencing disease control. Among 20 evaluable patients with microsatellite stable colorectal cancer (MSS-CRC), where PD-1 inhibitors have historically shown limited to no activity2-5, there were three confirmed PRs and one unconfirmed PR. In addition, ten cases of stable disease (SD) were observed, with one patient’s tumor burden reduced by 27%. The disease control rate (DCR) among these MSS CRC patients was 70%. Among 9 evaluable ovarian cancer patients receiving at least 1 mg/kg of AGEN1181 in combination with balstilimab, there were three confirmed PRs and two cases of SD (one of the patients with SD had a 28% reduction of tumor burden). Compelling clinical activity was also seen in MSS-endometrial cancer as both patients treated with combination therapy demonstrated PRs; all three patients with MSS endometrial cancer treated with AGEN1181 (one with monotherapy, two in combination with balstilimab) had objective responses. Additional responders to combination therapy include 1 confirmed PR in a NSCLC patient who failed prior PD-1 therapy, 2 confirmed PRs in visceral angiosarcoma, and 1 unconfirmed PR in leiomyosarcoma.

Neutral

Agenus Inc. has filed a Shelf Registration in the amount of $2.8145 million.

2021-11-12 00:00:00

Agenus Inc. has filed a Shelf Registration in the amount of $2.8145 million. Security Name: Common Stock Securities Offered: 650,000

Neutral

Agenus Inc. Presents at Society for Immunotherapy of Cancer's 36th Annual Meeting, Nov-12-2021

2021-11-04 12:30:00

Agenus Inc. Presents at Society for Immunotherapy of Cancer's 36th Annual Meeting, Nov-12-2021 . Venue: Walter E. Washington Convention Center, District Of Columbia, Washington, United States. Speakers: Manuel Hidalgo, Member of Scientific Advisory Board, Steven J. O’Day, Chief Medical Officer.

Neutral

Agenus Inc., Q3 2021 Earnings Call, Nov 09, 2021

2021-10-25 12:30:00

Agenus Inc., Q3 2021 Earnings Call, Nov 09, 2021

Neutral

Agenus Inc. to Report Q3, 2021 Results on Nov 09, 2021

2021-10-25 12:30:00

Agenus Inc. announced that they will report Q3, 2021 results Pre-Market on Nov 09, 2021

Neutral

Agenus Inc. - Special Call

2021-10-22 12:02:00

To announce a strategic decision to withdraw its Biologics License Application (BLA) for balstilimab, its PD-1 inhibitor

Positive

Agenus Provides Update on Balstilimab Development

2021-10-22 12:02:00

Agenus Inc. announced a strategic decision to withdraw its Biologics License Application (BLA) for balstilimab, its PD-1 inhibitor. The decision to withdraw the BLA does not change the development plans for balstilimab combinations. Following the full approval of pembrolizumab, announced four months earlier than the FDA goal date, the U.S. Food and Drug Administration (FDA) no longer considered it appropriate to review the BLA for accelerated approval and recommended Agenus withdraw. The BLA submission for balstilimab received Fast Track and Priority Review designation from the FDA, with a target action date of December 16, 2021. As part of the BLA review process, Agenus successfully completed 3 FDA inspections with no cited issues, concerns, or Form-483s. Agenus plans to launch expanded access programs to give patients access to balstilimab in several countries, including the US. Agenus will discontinue its ongoing confirmatory trial (BRAVA) in this population, which is expected to reduce R&D expenses by over $100 million. Accelerated development of balstilimab in combination with AGEN1181 will be launched in multiple tumor types; clinical update at SITC.

Neutral

Agenus Inc. Presents at TIGIT Therapies Digital Summit, Dec-07-2021

2021-10-12 17:24:00

Agenus Inc. Presents at TIGIT Therapies Digital Summit, Dec-07-2021 . Speakers: Dhan Chand, Scientific Director & Head of Drug Discovery.

Neutral

Agenus Inc. to Receive $20 million Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with Its TIGIT Bispecific Antibody

2021-10-12 12:30:00

Agenus Inc. announced it has triggered the first development milestone payment under its global licensing agreement with Bristol Myers Squibb for AGEN1777, an Fc-enhanced bispecific anti-TIGIT antibody. Agenus will receive a $20 million cash payment with the dosing of the first patient. This Phase 1 dose escalation study is designed to evaluate the safety, tolerability, and preliminary clinical activity of AGEN1777 as a single agent and in combination with a PD-1 inhibitor in patients with advanced solid tumors. The first patient was treated at Providence Cancer Institute by Dr. Rachel Sanborn. The trial will follow a standard dose-escalation design and will be used to establish the recommended Phase 2 dose (RP2D). Bristol Myers Squibb intends to advance the research and development of AGEN1777 in immuno-oncology for high priority tumor indications including non-small cell lung cancer. The global license agreement with Bristol Myers Squibb included a $200 million upfront payment paid in July 2021, and up to $1.36 billion in development, regulatory and commercial milestones in addition to tiered double-digit royalties on net product sales. Bristol Myers Squibb is solely responsible for the development and commercialization of AGEN1777 and its related products worldwide. Agenus retains options to conduct clinical studies under the development plan, to conduct combination studies with certain other Agenus pipeline assets, to co-fund global development for increased US royalties, and to co-promote AGEN1777 in the US upon commercialization.

Neutral

Hanson Wade Limited, TIGIT Therapies Digital Summit, Dec 07, 2021 through Dec 09, 2021

2021-10-12 06:21:00

Hanson Wade Limited, TIGIT Therapies Digital Summit, Dec 07, 2021 through Dec 09, 2021.

Neutral

Agenus Inc. Presents at BioFuture, Oct-05-2021 01:30 PM

2021-10-05 14:34:00

Agenus Inc. Presents at BioFuture, Oct-05-2021 01:30 PM. Venue: The Lotte Palace Hotel, New York City, New York, United States. Speakers: Jennifer Buell, President & COO.

Neutral

Agenus Inc. Presents at Longwood Healthcare Leaders Conference, Oct-04-2021 04:10 PM

2021-09-28 18:44:00

Agenus Inc. Presents at Longwood Healthcare Leaders Conference, Oct-04-2021 04:10 PM. Speakers: Jennifer Buell, President & COO.

Neutral

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021

2021-09-28 13:09:00

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021.

Neutral

Agenus Inc. Presents at Festival of Biologics Basel 2021, Nov-09-2021

2021-09-22 15:38:00

Agenus Inc. Presents at Festival of Biologics Basel 2021, Nov-09-2021 . Venue: Congress Centre, Basel, Switzerland. Speakers: Emmanuel Briend, Associate Antibody Discovery Director.

Neutral

Agenus Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-19-2021 05:35 PM

2021-09-16 22:25:00

Agenus Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-19-2021 05:35 PM. Venue: Paris Expo Porte de Versailles, Paris, France. Speakers: David O’Malley.

Positive

Agenus Inc. Announces New Subsidiary, SaponiQx

2021-09-10 11:30:00

Agenus Inc. announced the launch of SaponiQx, a subsidiary of Agenus, dedicated to driving innovation in novel adjuvant discovery and vaccine design, and its partnership with Ginkgo Bioworks Inc. (“Ginkgo”), the leading horizontal platform for cell programming. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. is enabling customers across industries to improve products and manufacturing processes, and to increase efficiency and sustainability, by making biology easier to engineer. SaponiQx is building an innovative adjuvant platform to deliver both sustainable manufacturing approaches and a secure supply of known adjuvants, as well as discover novel adjuvants and develop new, more effective vaccines utilizing optimized antigen-adjuvant pairings. Adjuvants are substances known to enhance the body’s immune response and are a key component of many existing vaccines. Ginkgo’s experience in metabolic engineering, enzymatic diversification, and process optimization can be applied to discover novel adjuvants and improve current manufacturing processes that can then be applied toward developing better-integrated vaccines.

Neutral

Agenus Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM

2021-09-09 12:00:00

Agenus Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States. Speakers: Jennifer Buell, President & COO.

Neutral

Agenus Inc. Presents at Baird Global Healthcare Conference 2021, Sep-15-2021 04:20 PM

2021-08-26 17:20:00

Agenus Inc. Presents at Baird Global Healthcare Conference 2021, Sep-15-2021 04:20 PM. Speakers: Jennifer Buell, President & COO.

Positive

Agenus Inc. Announces Balstilimab Monotherapy Data Published in Gynecologic Oncology

2021-08-26 13:00:00

Agenus Inc. announced that results from a global Phase 2 clinical study of balstilimab monotherapy in recurrent/metastatic cervical cancer were published online in the international peer reviewed journal Gynecologic Oncology. In the 140 evaluable patients, the objective response rate (ORR) in patients with PD-L1 positive tumors was 20.0% and included 3 patients (3/85, 3.5%) with a complete response and 14 patients (14/85, 16.5%) with a partial response. The median duration of response (DoR) was not reached after a 14.6-month median follow-up. Responses were also observed in the PD-L1 negative population with an ORR of 7.9%. The confirmed ORR for both PD-L1 positive and negative tumors was 15.0% and included 5 patients (3.6%) with a complete response and 16 patients (11.4%) with a partial response. The median DoR was 15.4 months and the disease control rate was ~50%. Notably, responses were observed across histologies, with responses in the squamous cell histology (ORR 17.6%) and in the more difficult to treat adenocarcinoma histology (ORR 12.5%). The safety profile was manageable and consistent with that of currently approved anti-PD-1 antibodies; it also compared favorably to the safety profiles of chemotherapies used in this population. Data from this trial continue to mature. As discussed in the publication, these data suggest that balstilimab may be a differentiated anti-PD-1 antibody as compared to currently approved PD-1 inhibitors. In the KEYNOTE-158 trial of pembrolizumab, an anti-PD-1 antibody, in the same setting, an ORR of 14.6% was observed in the PD-L1 positive population and no responses were observed in the PD-L1 negative population. In addition, the noted 12.5% response rate of balstilimab in patients with cervical adenocarcinoma is significant as this subpopulation typically does not respond to immunotherapy and represents a growing proportion of advanced cervical cancer cases. Balstilimab thus provides the potential for therapeutic benefit to patient populations that do not typically respond to currently-available immunotherapy, both alone and in combination with other therapies, such as Agenus’ anti-CTLA-4 antibodies zalifrelimab and AGEN1181.

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Neutral

Society for Immunotherapy of Cancer, Inc., Society for Immunotherapy of Cancer's 36th Annual Meeting, Nov 10, 2021 through Nov 14, 2021

2021-08-17 11:12:00

Society for Immunotherapy of Cancer, Inc., Society for Immunotherapy of Cancer's 36th Annual Meeting, Nov 10, 2021 through Nov 14, 2021. Venue: Walter E. Washington Convention Center, District Of Columbia, Washington, United States.

Neutral

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Negative

Agenus Inc. Promotes Julie DeSander to Chief Business Officer

2021-08-09 11:45:00

Agenus Inc. announced that Julie DeSander promoted to Chief Business Officer.

Neutral

Agenus Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-09-2021 03:00 PM

2021-08-02 20:05:00

Agenus Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-09-2021 03:00 PM. Speakers: Jennifer Buell, President & COO.

Negative

Agenus Inc. Announces Resignation of Adam F. Krauss, Chief Legal Officer and Chief Compliance Officer, Effective July 30, 2021

2021-07-26 20:44:00

On July 20, 2021, Adam F. Krauss, Chief Legal Officer and Chief Compliance Officer of Agenus Inc. provided notice that he will be stepping down from his role effective July 30, 2021.

Neutral

Agenus Inc. to Report Q2, 2021 Results on Aug 09, 2021

2021-07-26 20:05:00

Agenus Inc. announced that they will report Q2, 2021 results Pre-Market on Aug 09, 2021

Neutral

Agenus Inc., Q2 2021 Earnings Call, Aug 09, 2021

2021-07-26 20:05:00

Agenus Inc., Q2 2021 Earnings Call, Aug 09, 2021

Positive

Agenus Inc. (NasdaqCM:AGEN) acquired Biomanufacturing Center in Vacaville California, US State from A.G. Spanos Companies.

2021-07-09 00:00:00

Agenus Inc. (NasdaqCM:AGEN) acquired Biomanufacturing Center in Vacaville California, US State from A.G. Spanos Companies on July 9, 2021. Agenus Inc. (NasdaqCM:AGEN) completed the acquisition of Biomanufacturing Center in Vacaville California, US State from A.G. Spanos Companies on July 9, 2021.

Neutral

Agenus Inc. Presents at William Blair Biotech Focus Conference 2021, Jul-14-2021 04:20 PM

2021-07-07 20:05:00

Agenus Inc. Presents at William Blair Biotech Focus Conference 2021, Jul-14-2021 04:20 PM. Speakers: Steven J. O’Day, Chief Medical Officer.

Neutral

Agenus Inc. Announces the Closing of its Global Exclusive License with Bristol Myers Squibb

2021-07-06 12:30:00

Agenus Inc. announced the closing of its global exclusive license with Bristol Myers Squibb for Agenus’ proprietary bispecific antibody program, AGEN1777, and the U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for this therapy. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. Bristol Myers Squibb intends to advance the research and development of AGEN1777 in immuno-oncology for high priority tumor indications including non-small cell lung cancer. Phase 1 dosing for AGEN1777 is expected to begin during the third quarter of 2021. This dose escalation study is designed to evaluate the safety, tolerability, and preliminary clinical activity of AGEN1777 as a single agent and in combination with a PD-1 inhibitor in patients with advanced solid tumors. Under the terms of the agreement with Bristol Myers Squibb, Agenus receives a $200 million upfront payment in connection with the closing. The agreement also includes up to $1.36 billion in development, regulatory and commercial milestones in addition to tiered double-digit royalties on net product sales. Bristol Myers Squibb will become solely responsible for the development and any subsequent commercialization of AGEN1777 and its related products worldwide. Agenus will retain options to conduct clinical studies under the development plan, to conduct combination studies with certain other Agenus pipeline assets, and also, upon commercialization, to co-promote AGEN1777 in the US. AGEN1777 is a potentially first-in-class bispecific anti-TIGIT antibody engineered with an enhanced Fc region for high binding affinity and improved T and NK cell activation.

Positive

Agenus Inc. Announces the U.S. Food and Drug Administration Clearance of an Investigational New Drug Application for Therapy, AGEN1777

2021-07-06 12:30:00

Agenus Inc. announced the U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for this therapy. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. Bristol Myers Squibb intends to advance the research and development of AGEN1777 in immuno-oncology for high priority tumor indications including non-small cell lung cancer. Phase 1 dosing for AGEN1777 is expected to begin during the third quarter of 2021. This dose escalation study is designed to evaluate the safety, tolerability, and preliminary clinical activity of AGEN1777 as a single agent and in combination with a PD-1 inhibitor in patients with advanced solid tumors. Under the terms of the agreement with Bristol Myers Squibb, Agenus receives a $200 million upfront payment in connection with the closing. The agreement also includes up to $1.36 billion in development, regulatory and commercial milestones in addition to tiered double-digit royalties on net product sales. Bristol Myers Squibb will become solely responsible for the development and any subsequent commercialization of AGEN1777 and its related products worldwide. Agenus will retain options to conduct clinical studies under the development plan, to conduct combination studies with certain other Agenus pipeline assets, and also, upon commercialization, to co-promote AGEN1777 in the US. AGEN1777 is a potentially first-in-class bispecific anti-TIGIT antibody engineered with an enhanced Fc region for high binding affinity and improved T and NK cell activation.

Neutral

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021

2021-07-01 10:09:00

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.

Fundamental Summary

At a high level, the metrics from Agenus's Q1 financial report release were demonstrably negative. Their income and value factors performance indicate that company management is missing the critical targets and not executing well. These troubling results make a strong case for underperformance and for anticipating a significant downside. We gave Agenus a 57 rating and a UNDERPERFORM recommendation.

Agenus reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 25.94 million compared to USD 11.72 million a year ago. Net loss was USD 48.33 million compared to USD 53.68 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 0.27 a year ago.

Business Description

Agenus, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus in January 2011. Agenus was founded in 1994 and is headquartered in Lexington, Massachusetts.

Sector Overview

Agenus is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Agenus's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 441.3 -5.3% 62
Liabilities 413.7 -1.1% 73
Price to Book 26.6 10.9% 60
Cash & Equivalents 247.7 -15.1% 55
Equity 15.7 -54.4% 37
EBITDA 61.5 13.6% 83
Total Revenues 309.9 4.8% 57
Parameter Value Change Score
Return on Equity 33.8 -19.7% 45
Net Cashflow 128.3 -33.2% 57
Capital Expenditure -32.5 -15.4% 52
Asset Turnover 0.9 5.5% 77
Free Cashflow -0.2 -49.7% 43

* All values are TTM

The below chart reflects Agenus's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Agenus's peer average final assessment score stands on 64.0, Agenus's score is 57.

  •  AGEN
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 0 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 1 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 2 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 3 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 4 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 6 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 7 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 8 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 9 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 10 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 11 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 12 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 13 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 14 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 15 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 16 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 17 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 18 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 20 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 21 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 22 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 24 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 25 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 26 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 27 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 28 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 29 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 30 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 32 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 33 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 34 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 35 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 36 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 37 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 39 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 40 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 41 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 42 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 43 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 44 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 45 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 47 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 48 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 50 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 51 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 54 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 55 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 56 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 57 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 59 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 60 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 61 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 62 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 63 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 64 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 65 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 66 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 68 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 69 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 73 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 74 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 75 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 76 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 77 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 80 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 81 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 82 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 83 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 84 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 86 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 87 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 88 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 89 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 90 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 91 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 92 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 93 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Agenus's stock is now priced above its 50-day, but below its 5-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Agenus's stock indicates that it's likely oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 62.

Neutral 62
Close Price 1.84
52W Low 1.3
52W High 6.63
5D MA 1.88
50D MA 1.72
200D MA 3.09
MACD 0.04
RSI 3.4
STOCH 79.41

Balance Sheet Analysis

A few metrics from Agenus's current balance sheet were especially concerning: Equity and Cash & Equivalents. Agenus management produced disappointing equity metrics this period, which stood at 15.7, representing a -54.4% change. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. Their equity metrics appear unremarkable relative to their peers. Therefore, their equity movement component earned a score of 37. Also, Agenus did a poor job related to managing cash and cash equivalents this period, which stood at 247.7, representing a -15.1% change from the previous filing. This performance is significantly less impressive than its peers and competitors. Its cash and cash equivalents movement, therefore, received a grade of 55. That said, one metric, Liabilities, stood out as strongly positive. Agenus is doing a good job of keeping its liabilities under control and growing intelligently. At filing, their liabilities were 413.7, representing -1.1% change from the previous period. These numbers show that management has successfully encouraged growth while managing liabilities, especially relative to their peers. The company's liabilities movement component, therefore, received a grade of 73. Therefore, the company's balance sheet earned a grade of 54.

Parameter Value Change Score
Assets 441.3 -5.3% 62
Liabilities 413.7 -1.1% 73
Price to Book 26.6 10.9% 60
Cash & Equivalents 247.7 -15.1% 55
Equity 15.7 -54.4% 37
* All values are TTM

The below chart describes Agenus's performance as reflected on its balance sheet with respect to its peers. While Agenus received a balance sheet score of 54, the average of its peers stands on 62.0.

  •  AGEN
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 0 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 1 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 2 1
Vericel Corporation 1.1B 51 65 56 53 61 57 3 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 4 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 6 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 7 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 8 1
Immatics N.V. 538.7M 56 70 84 95 73 76 9 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 10 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 11 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 12 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 13 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 14 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 15 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 16 1
Amgen Inc. 130.1B 72 68 86 53 62 69 17 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 18 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 20 1
BioNTech SE 34.0B 75 69 64 97 73 75 21 1
Seagen Inc. 32.9B 59 68 55 43 66 61 22 1
Biogen Inc. 29.7B 57 72 92 50 76 76 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 24 1
Incyte Corporation 16.8B 71 72 95 82 79 83 25 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 26 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 27 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 28 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 29 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 30 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 31 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 32 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 33 1
Alkermes plc 5.0B 63 66 46 54 71 62 34 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 35 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 36 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 37 1
Natera, Inc. 3.6B 73 65 43 95 42 54 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 39 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 40 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 41 1
CureVac N.V. 2.6B 49 64 75 52 52 57 42 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 43 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 44 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 45 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 47 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 48 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 50 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 51 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 54 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 55 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 56 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 57 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 59 1
CareDx, Inc 1.2B 54 67 52 39 51 52 60 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 61 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 62 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 63 1
MannKind Corporation 957.2M 79 59 50 40 64 57 64 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 65 1
Merus N.V. 941.6M 59 68 50 83 81 70 66 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 68 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 69 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 73 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 74 1
Geron Corporation 566.2M 69 72 37 59 62 60 75 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 76 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 77 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
Affimed N.V. 415.0M 56 66 63 56 47 54 80 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 81 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 82 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 83 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 84 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 86 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 87 1
AC Immune SA 299.8M 84 64 47 53 75 68 88 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 89 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 90 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 91 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 92 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 93 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Agenus seems to be balancing strong EBITDA and Revenue Efficiency along with an overall impressive positive income statement. Agenus's management did a remarkable job this period managing its EBITDA. In terms of the raw numbers, EBITDA was reported as 61.5, which represents a 13.6% change from the last period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Its EBITDA metrics highlight an impressive overall financial performance, which is expected to continue moving forward. Therefore, its EBITDA component earned a score of 83. Also, Agenus reported highly encouraging numbers for its revenue efficiency. This parameter often affects companies in the same industry and market capitalization by up to 13.1%. Their impressive revenue efficiency is even more impressive relative to its peers and competitors in the current market. Consequently, their revenue efficiency received a grade of 57. That said, one metric, Return Factors, stood out as strongly negative. In this filing, Agenus reported a return on equity (ROE) ratio of 33.8, which represents a growth of -19.7%. This metric might have a 3.6 percent impact on companies in the same industry and with the same market capitalization. The company's return factor metrics return on equity and return on assets are even more concerning when compared to their peers. Its return factors (ROA & ROE) components, therefore, received a grade of 45. Because its management is doing an excellent job managing these critical metrics, the income statement was given a score of 74.

Parameter Value Change Score
EBITDA 61.5 13.6% 83
Total Revenues 309.9 4.8% 57
Return on Equity 33.8 -19.7% 45
* All values are TTM

The below chart describes Agenus's performance as reflected on its income statement with respect to its peers. While Agenus received a income statement score of 74 , the average of its peers stands on 68.0.

  •  AGEN
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Exact Sciences Corporation 7.2B 57 67 54 62 0 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 1 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 2 1
Vericel Corporation 1.1B 76 44 82 56 3 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 4 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 6 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 7 1
CTI BioPharma Corp. 603.6M 84 50 62 59 8 1
Immatics N.V. 538.7M 37 93 53 77 9 1
Vaxart, Inc. 440.0M 99 51 72 68 10 1
MiMedx Group, Inc. 391.5M 87 43 83 59 11 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 12 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 13 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 14 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 15 1
DermTech, Inc. 165.3M 49 48 78 52 16 1
Amgen Inc. 130.1B 74 75 64 78 17 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 18 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 20 1
BioNTech SE 34.0B 41 89 75 79 21 1
Seagen Inc. 32.9B 54 65 70 62 22 1
Biogen Inc. 29.7B 90 57 73 70 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 24 1
Incyte Corporation 16.8B 59 77 60 73 25 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 26 1
United Therapeutics Corporation 10.6B 57 91 54 82 27 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 28 1
Exelixis, Inc. 6.7B 54 91 54 81 29 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 30 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 32 1
Ascendis Pharma A/S 5.2B 38 68 46 54 33 1
Alkermes plc 5.0B 69 55 81 62 34 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 35 1
Novavax, Inc. 4.0B 41 89 54 75 36 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 37 1
Natera, Inc. 3.6B 52 51 78 52 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 39 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 40 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 41 1
CureVac N.V. 2.6B 45 83 71 74 42 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 43 1
Insmed Incorporated 2.4B 51 58 73 57 44 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 45 1
Abgenix Inc. 2.1B 47 47 47 47 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 47 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 48 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 50 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 51 1
Xencor, Inc. 1.6B 42 94 52 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 54 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 55 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 56 1
Veracyte, Inc. 1.4B 45 63 57 55 57 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 58 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 59 1
CareDx, Inc 1.2B 61 44 82 50 60 1
IVERIC bio, Inc. 1.1B 84 58 79 70 61 1
FibroGen, Inc. 1.0B 48 74 63 67 62 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 63 1
MannKind Corporation 957.2M 95 48 56 61 64 1
ImmunoGen, Inc. 946.1M 40 73 71 64 65 1
Merus N.V. 941.6M 48 60 59 54 66 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 68 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 69 1
Amarin Corporation plc 734.5M 95 44 82 63 70 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 73 1
AnaptysBio, Inc. 586.3M 97 50 77 68 74 1
Geron Corporation 566.2M 89 67 73 78 75 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 76 1
Radius Health, Inc. 499.8M 94 71 68 82 77 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
Affimed N.V. 415.0M 95 49 75 66 80 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 81 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 82 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 83 1
Zymeworks Inc. 324.7M 58 53 77 56 84 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 86 1
Silence Therapeutics plc 313.4M 83 64 69 72 87 1
AC Immune SA 299.8M 83 61 65 70 88 1
Precigen, Inc. 299.1M 57 87 59 79 89 1
bluebird bio, Inc. 288.7M 99 91 61 96 90 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 91 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 92 1
MacroGenics, Inc. 184.6M 95 56 74 71 93 1
Chimerix, Inc. 178.4M 99 50 62 65 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Results from Agenus's current financials were concerning, in two areas in particular: Free Cash flow and Capital Expenditure. Free cash flow numbers published by Agenus were -0.2, which was a -49.7% change from the previous filing. Companies in the same sector and market capitalization will usually be affected by up to 2.6 percent by this parameter. These free cash flow numbers show that management has not been executing well in generating critical cash flow while also encouraging growth. Its free cash flow movement, therefore, received a grade of 43. Also, Agenus's published capital expenditures (CapEx) numbers were discouraging and reflected management's unbalanced growth strategy. Agenus recorded CapEx of -32.5, which represents a -15.4% change from the previous report. This performance is all the more uninspiring relative to their peers and competitors. Therefore, their CapEx movement component earned a score of 52. On the other hand, Asset Turnover, jumped out as looking rather positive. Agenus's published asset turnover numbers were encouraging and reflected management's balanced change strategy. Agenus recorded asset turnover of 0.9, which represents a 5.5% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. Their asset turnover numbers are significantly more impressive when contrasted against their peers and competitors. The company's asset turnover movement, therefore, received a grade of 77. Because of these weaknesses, their cash flow received an overall score of 58.

Parameter Value Change Score
Net Cashflow 128.3 -33.2% 57
Capital Expenditure -32.5 -15.4% 52
Asset Turnover 0.9 5.5% 77
Free Cashflow -0.2 -49.7% 43
* All values are TTM

The below chart describes Agenus's performance as reflected on its cash flow with respect to its peers. While Agenus received a cash flow score of 58, the average of its peers stands on 69.0.

  •  AGEN
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Exact Sciences Corporation 7.2B 53 45 80 46 56 0 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 1 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 2 1
Vericel Corporation 1.1B 64 46 59 73 65 3 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 4 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 6 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 7 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 8 1
Immatics N.V. 538.7M 82 95 56 99 86 9 1
Vaxart, Inc. 440.0M 72 56 53 38 65 10 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 11 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 12 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 13 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 14 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 15 1
DermTech, Inc. 165.3M 60 51 45 86 58 16 1
Amgen Inc. 130.1B 80 74 67 74 81 17 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 18 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 20 1
BioNTech SE 34.0B 73 97 50 52 72 21 1
Seagen Inc. 32.9B 53 53 50 87 58 22 1
Biogen Inc. 29.7B 58 54 90 73 66 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 24 1
Incyte Corporation 16.8B 78 79 92 74 84 25 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 26 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 27 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 28 1
Exelixis, Inc. 6.7B 79 90 89 83 87 29 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 30 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 31 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 32 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 33 1
Alkermes plc 5.0B 89 95 76 80 92 34 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 35 1
Novavax, Inc. 4.0B 62 38 63 54 60 36 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 37 1
Natera, Inc. 3.6B 52 54 56 84 58 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 39 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 40 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 41 1
CureVac N.V. 2.6B 87 80 90 70 90 42 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 43 1
Insmed Incorporated 2.4B 79 80 61 89 82 44 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 45 1
Abgenix Inc. 2.1B 66 53 45 59 58 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 47 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 48 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 50 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 51 1
Xencor, Inc. 1.6B 96 95 70 95 98 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 54 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 55 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 56 1
Veracyte, Inc. 1.4B 90 95 46 46 82 57 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 58 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 59 1
CareDx, Inc 1.2B 98 84 40 50 86 60 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 61 1
FibroGen, Inc. 1.0B 86 74 48 87 84 62 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 63 1
MannKind Corporation 957.2M 77 56 43 37 66 64 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 65 1
Merus N.V. 941.6M 70 71 74 53 71 66 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 68 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 69 1
Amarin Corporation plc 734.5M 52 40 74 55 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 73 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 74 1
Geron Corporation 566.2M 78 68 49 81 77 75 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 76 1
Radius Health, Inc. 499.8M 64 40 37 56 57 77 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
Affimed N.V. 415.0M 72 57 95 43 74 80 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 81 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 82 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 83 1
Zymeworks Inc. 324.7M 52 65 45 83 57 84 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 86 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 87 1
AC Immune SA 299.8M 66 77 79 63 68 88 1
Precigen, Inc. 299.1M 82 75 37 85 74 89 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 90 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 91 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 92 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 93 1
Chimerix, Inc. 178.4M 80 84 95 47 83 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.